RE:RE:RE:Good deal or not? I guess there are competing forces at play here. There is no treatment atm, so going from that base you have a lot to build visibility. But there seems to be a fairly interesting infrastructure around for other "founder effect" diseases in Quebec and presumably this infrastructure will kick in once a treatment is available for FCS. The strategy must be to focus on these populations with higher rates at the start. It's interesting to imagine the Qc state has some interest in tackling these 'Quebec specific' health challenges.
Maxmoe wrote: Or asked another way. How much if a sales "team" do you need if it's the only treatment available?